Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 14/20 | 1.00 |
| ▸ | RAB9A | P51151 | 14/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TOP1 | P11387 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13657955 | 0.85 | NPC1 (0.74) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL11342741 | 0.85 | NPC1 (0.74) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL11345273 | 0.82 | NPC1 (0.73) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL11351283 | 0.82 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL11346555 | 0.82 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL6340695 | 0.79 | NPC1 (0.77) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL14757358 | 0.79 | NPC1 (0.78) | NPC1RAB9ASMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL14757375 | 0.78 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL14642683 | 0.78 | NPC1 (0.72) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL11347416 | 0.77 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900219-B2 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1513534-A2 | COMPOUNDS FOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20030220356-A1 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003084544-A2 | COMPOUNDS DOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220356-A1 | ABCA-1 elevating compounds | ABCD3, ABCE1, ABCB4 | NPC1 6/4885RAB9A 2138/4885SMN1; SMN2 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.